Algen Biotechnologies

At Acrigen, we believe that gene editing will revolutionize medicine and bring hope to millions of patients suffering from genetic diseases. We are developing Precision Gene Editing Systems to harness the power of CRISPR for use in human therapeutics. Acrigen’s proprietary technology leverages novel αCas and μCas CRISPR gene editors coupled with ErAcrs (engineered anti-CRISPR proteins) to create an editing toolbox with best-in-class efficiency and precision. Acrigen has discovered and engineered αCas and μCas, 2 families of novel CRISPR-Cas nucleases fine tuned for human gene editing.

Algenex has an established track record as a producer of antigens proteins for the human and animal diagnostic and therapeutic markets and has also demonstrated the applicability of its technology platform CrisBio® to on-demand production of growth factors, enzymes and cytokines. VC-backed technology company developing disruptive technologies to boost recombinant biologics production using proprietary technologies based on Baculovirus vector expression systems (BVES) in insect cells. Building on experience in animal health, Algenex is expanding the production of proteins into human health to fully exploit the potential of its technology platforms.

We boldly create novel and elegant CRISPR solutions to make a positive and profound impact on human health. From the very start we knew that CRISPR had the potential to cure the most complex genetic diseases, but limitations of the original CRISPR-Cas9 system prevented this vision from being fully realized. So we flipped the CRISPR script to first understand each genetic disease and then devise an optimal editing strategy. At EmendoBio, we’ve brought together a world class multifaceted team to evolve traditional CRISPR tools and create entirely new nucleases customized to any genetic disease. We come to work knowing every challenge we face can be overcome.

We are pioneering a new era of medicines. We are pioneers of the CRISPR technology and at the forefront of what’s next. The first-ever CRISPR-based therapy is a direct reflection of our patient-forward philosophy. We believe this once-in-a-generation breakthrough will make an impact for generations to come. CRISPR Therapeutics is founded, launching the growth of our team focused on translating the CRISPR/Cas9 discovery into potential therapeutics. Opens the doors to its own manufacturing facility in Framingham, Massachusetts. Where we’ve built our state-of-the-art, award-winning manufacturing facility.*. Here we focus on the most advanced gene editing and delivery technologies of the future.

Join our mission to engineer the next 20 years of gene editing breakthroughs - today. Pioneering novel viral and non-viral delivery technologies to truly enable in vivo genetic medicine. Built for exceptional specificity within the genome – enabling therapeutic precision and allele specific targeting.

First, using computational tools we study which genes are responsible for a desirable trait in order to develop the most promising plants. Then, we edit the genes of interest using proprietary CRISPR-Cas9 tools creating Non-GMO plants that will grow in controlled environments reaching their highest genetic potential. Finally, we validate the new gene-edited plants with improved traits in field conditions. The data obtained is used to feed and reinforce our technology platform. © Copyright Calice Biotech 2023 | Todos los derechos reservados.